Brian T. Powl is CCO at Kura Oncology, Inc. (KURA). They have made 5 open-market trades across 2 companies since 2023, most recently 2026-09-29.
CIK 0001934232
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KURA | 136,819 | $1.0M |
| FATE | 41,146 | $86K |
| Total | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-29 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KURA | SELL · 10b5-1 | 2026-09-28 | 2026-09-29 | $10.63 | $345K | -2.4% | -1.5% | — |
| KURA | SELL · 10b5-1 | 2026-08-21 | 2026-08-24 | $11.89 | $52K | -5.5% | -15.5% | — |
| KURA | SELL · 10b5-1 | 2026-05-21 | 2026-05-22 | $11.00 | $110K | -22.1% | -7.7% | +4.2% |
| KURA | SELL · 10b5-1 | 2026-05-19 | 2026-05-20 | $9.21 | $3K | -13.7% | -0.2% | +18.7% |
| KURA | SELL | 2026-01-27 | 2026-01-27 | $8.46 | $54K | -7.2% | +2.5% | +7.6% |
| KURA | SELL | 2025-11-14 | 2025-11-14 | $11.18 | $199K | +7.4% | -5.4% | -28.1% |
| KURA | SELL | 2025-09-29 | 2025-09-29 | $8.94 | $159K | +15.3% | +15.4% | +17.5% |
| KURA | SELL | 2025-01-28 | 2025-01-28 | $7.87 | $12K | +12.3% | -0.6% | -15.5% |
| FATE | SELL | 2023-07-05 | 2023-07-06 | $4.87 | $19K | -1.9% | -24.1% | -62.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.